VivoSeq
Oncology

Prostate Cancer Metastatic

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Prostate Cancer Metastatic is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Completed1 · 33%
Enrolling by invitation1 · 33%

Clinical Trials

Trial Activity

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Metastatic Prostate Cancer
Recruiting·AAbramson Cancer Center at Penn Medicine·N/A·NCT05242744·30 enrolled
Comparison of Changes in Tumor Burden (Toral Tumor Volume [TMTV] and Total Lesion Activity [TLA]) in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in the Monitoring of Metastatic Castration-resistant Prostate Cancer Treated With 177Lutetium-PSMA-617
Completed·CCentral Hospital, Nancy, France·N/A·NCT06461689·80 enrolled
Development and Validation of an AI-Based Metastasis Prediction Model Using Prostate Cancer Biopsy Pathology
Enrolling by invitation·XXiangya Hospital of Central South University·N/A·NCT07660276·3,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)